Özet:

Type 2 diabetes is the most common form of diabetes and characterized by insulin resistance and hyperglycemia. It is known that the increase in the number of obese individuals is related to the increase in the number of type 2 diabetes. In our study, it was aimed to investigate the effect of sitagliptin on the changes of cholecystokine (CCK) and cannabinoid (CB) 1 receptor peptides in newborn STZ-diabetic rat stomach and duodenum. Materials and methods: Wistar albino newborn rats divided into four groups. Group I: The saline was administered intraperitoneally (i.p) to rats. Group II: Newborn rat group, from the day five sitagliptin that dissolved in the saline was injected 1.5 mg/kg subcutaneous (s.c) for 15 days. Group III: Second day after the birth 100 mg/kg streptozotocin was administered for a single dose to the newborn diabetic rats (Diabetes). Group IV: Sitagliptin was given to diabetic rats for 15 days (Diabetes+Sitagliptin). Sections were stained with CCK and CB-1 receptor antibodies by streptavidin-biotin peroxidase technique. Results:The body weight was decreased in diabetic rats treated with sitagliptin when compared to diabetic rats. The number of CCK immune-positive cells in the stomach decreased slightly in diabetic rats as compared to control, while increase was observed in duodenum. The number of CB1 receptor immune-positive cells in the stomach and duodenum did not show any change between control and diabetes groups. A significant decrease determined in CCK and CB1 receptor immune-positive cell numbers in duodenum of Diabetes+Sitagliptin group as compared with diabetes group.Conclusion: According to our findings, sitagliptin may be used a regulatory on weight gain for treatment of obesity induced-diabetes.

Anahtar Kelimeler: